BioCentury
ARTICLE | Top Story

Dezima CETP inhibitor meets endpoint in dyslipidemia trial

August 30, 2014 12:23 AM UTC

Dezima Pharma B.V. (Naarden, the Netherlands) said TA-8995 ( DEZ-001) alone or in combination with statin therapy met the primary endpoint vs. placebo in the 364-patient Phase IIb TULIP trial to treat dyslipidemia. The primary endpoint was a composite of the change from baseline in LDL-C and HDL-C at week 12.

Dezima plans to publish full data in the coming months and start a Phase III trial next year. The company has exclusive, worldwide rights, excluding certain Asian territories, to the cholesteryl ester transfer protein (CETP) inhibitor from Mitsubishi Tanabe Pharma Corp. (Tokyo:4508) (see BioCentury, Jan. 28, 2013). ...